A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02326454 |
Recruitment Status :
Completed
First Posted : December 29, 2014
Last Update Posted : August 8, 2018
|
Sponsor:
Light Sciences Oncology
Collaborator:
Mundipharma Research Limited
Information provided by (Responsible Party):
Light Sciences Oncology
- Study Details
- Tabular View
- Results Submitted
- FDAAA 801 Violations
- Disclaimer
- How to Read a Study Record
Information on FDAAA 801 Violations
More Information: Notices of Noncompliance [FDA]
Available on ClinicalTrials.gov | Issued by FDA | Study Record Submitted | Notice Type | FDAAA 801 Notice |
---|---|---|---|---|
December 7, 2023 | November 22, 2023 | August 2, 2023 | Issues in letter addressed; confirmed by FDA. | The responsible party has responded, and this matter was resolved administratively. |
July 31, 2023 | July 19, 2023 | August 6, 2018 | Violation Identified by FDA | Failure to Submit |